ifosfamide has been researched along with Lymphoma, Non-Hodgkin in 193 studies
Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 143 patients with relapsed (n = 90), primary refractory (n = 32) and first line chemotherapy responsive (n = 21) non-Hodgkin lymphoma (NHL) and Hodgkin disease (HD) were treated with IVE (ifosphamide, etoposide and epirubicin) chemotherapy with the intent to proceed to high-dose therapy with either autologous or allogeneic transplantation, following peripheral blood stem cell mobilisation." | 9.12 | Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. ( Bishton, MJ; Byrne, JL; Haynes, AP; Lush, RJ; Russell, NH; Shaw, BE, 2007) |
| "Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma." | 9.08 | Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. ( Ben-Shahar, M; Epelbaum, R; Haim, N, 1995) |
| "A three-drug combination of ifosfamide, epirubicin and etoposide (IEV) was used to treat 62 patients with relapsing or refractory aggressive non-Hodgkin's lymphoma (NHL; n=51) or Hodgkin's disease (HD; n=11)." | 7.71 | Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. ( Alinari, L; Baccarani, M; Bonifazi, F; Gabriele, A; Molinari, AL; Salvucci, M; Stefoni, V; Tani, M; Tura, S; Zinzani, PL; Zuffa, E, 2002) |
| "Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed." | 6.73 | Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007) |
| " Dosing was modified for elderly patients." | 5.72 | Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma. ( Borawska, A; Chełstowska, M; Dąbrowska-Iwanicka, A; Domańska-Czyż, K; Druzd-Sitek, A; Giebel, S; Knopińska-Posłuszny, W; Konecki, R; Kumiega, B; Lange, A; Malenda, A; Michalski, W; Mordak-Domagała, M; Najda, J; Osowiecki, M; Ostrowska, B; Paszkiewicz-Kozik, E; Pluta, A; Popławska, L; Romejko-Jarosińska, J; Rymkiewicz, G; Świerkowska, M; Szpila, T; Szymański, M; Targoński, Ł; Taszner, M; Walewski, J; Zaucha, JM, 2022) |
| "Eight patients had low-grade non-Hodgkin's lymphoma (NHL), 28 had high-grade NHL, and 11 patients had Hodgkin's disease." | 5.28 | Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas. ( Anders, CH; Moritz, T; Nagel-Hiemke, M; Niederle, N; Nowrousian, MR; Schmidt, CG; Seeber, S, 1991) |
| "A total of 143 patients with relapsed (n = 90), primary refractory (n = 32) and first line chemotherapy responsive (n = 21) non-Hodgkin lymphoma (NHL) and Hodgkin disease (HD) were treated with IVE (ifosphamide, etoposide and epirubicin) chemotherapy with the intent to proceed to high-dose therapy with either autologous or allogeneic transplantation, following peripheral blood stem cell mobilisation." | 5.12 | Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. ( Bishton, MJ; Byrne, JL; Haynes, AP; Lush, RJ; Russell, NH; Shaw, BE, 2007) |
| " Relapsing progressive lymphoma patients (n = 204; non-Hodgkin's lymphoma n = 166; Hodgkin's disease n = 38) were, after induction treatment with the DHAP-VIM (cisplatin, cytarabine, dexamethasone, etoposide, ifosfamide, methotrexate) regimen, randomly (2:1) assigned to the harvest of granulocyte-macrophage colony-stimulating factor-mobilized stem cells after the second DHAP course or autologous bone marrow cells before the second DHAP course." | 5.09 | Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. ( Croockewit, AJ; Fibbe, WE; Kingma, T; Uyl-de Groot, CA; van Agthoven, M; van Imhoff, GW; van Oers, MH; Vellenga, E; Verdonck, LF; Volkers, CP; Wijermans, PJ, 2001) |
| "Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma." | 5.08 | Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. ( Ben-Shahar, M; Epelbaum, R; Haim, N, 1995) |
| "Seventy-two patients with recurrent or refractory malignant lymphoproliferative diseases were treated with MIME combination chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) and concurrent mesna to prevent urothelial toxicity; 41 patients had high/intermediate-grade non-Hodgkin's lymphoma (NHL), 18 low-grade NHL/chronic lymphocytic leukemia (CLL), and 13 Hodgkin's disease (HD)." | 5.07 | MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study. ( Brincker, H; Mirza, MR, 1991) |
| " Patients who proceeded to haematopoietic stem cell transplants (HDTs) received conditioning therapy with BEAM [for the Hodgkin's Lymphoma (HL) and non-Hodgkin's Lymphoma (NHL) groups], or melphalan 100 mg/m2 and mitoxantrone [for the multiple myeloma (MM) patients]." | 3.73 | Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. ( Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R, 2005) |
| "A three-drug combination of ifosfamide, epirubicin and etoposide (IEV) was used to treat 62 patients with relapsing or refractory aggressive non-Hodgkin's lymphoma (NHL; n=51) or Hodgkin's disease (HD; n=11)." | 3.71 | Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. ( Alinari, L; Baccarani, M; Bonifazi, F; Gabriele, A; Molinari, AL; Salvucci, M; Stefoni, V; Tani, M; Tura, S; Zinzani, PL; Zuffa, E, 2002) |
| " Three groups of patients were prospectively evaluated: Group I: 15 patients with Wegener's granulomatosis and 4 patients with severe scleritis received a single dose cyclophosphamide (15 mg/kg bw/day) and 250 mg prednisone i." | 3.70 | Unique alterations of thyroid function parameters after i.v. administration of alkylating drugs (cyclophosphamide and ifosfamide). ( Jockenhövel, F; Kummer, G; Mann, K; Philipp, T; Reinhardt, W; Reinwein, D; Sauter, V; Uppenkamp, M; Witzke, O, 1999) |
| "Neuroblastomas, nephroblastomas, malignant mesenchymal tumors, including rhabdomyosarcomas, Ewing's sarcomas, osteosarcomas, brain tumors, and non-Hodgkin's lymphomas respond to ifosfamide monotherapy." | 3.69 | Ifosfamide in the treatment of pediatric malignancies. ( Behrendt, H; de Kraker, J; Michiels, E; van den Berg, H; Voûte, PA, 1996) |
| " Carfilzomib, an irreversible proteasome inhibitor, can overcome acquired rituximab-chemotherapy resistance and, when combined with R-ICE, improves outcomes in patients with R/R DLBCL." | 3.30 | Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. ( Burke, SM; Ghasemi, M; Goey, AKL; Hernandez-Ilizaliturri, FJ; Lin, LH; Mager, DE; Mavis, CK; Nichols, JR; Torka, P, 2023) |
| "Grade 3 and 4 infections occurred four times more frequently in the dose-dense arm." | 2.75 | Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma. ( Chott, A; Drach, J; Fridrik, MA; Geissler, D; Greil, R; Hausmaninger, H; Krieger, O; Lang, A; Michlmayr, G; Oberaigner, W; Ulsperger, E, 2010) |
| " These data may aid the design of studies to clarify optimal dosing and leukapheresis with pegfilgrastim." | 2.73 | A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. ( Baker, N; Barker, P; Boogaerts, M; Canizo, CD; Johnsen, HE; Mesters, R; Russell, N; Schmitz, N; Schubert, J; Skacel, T, 2008) |
| "Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed." | 2.73 | Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007) |
| "Acute renal failure and bacterial infection occurred as non-hematologic dose limiting toxicities." | 2.70 | A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation. ( de Magalhaes-Silverman, M; Gingrich, RD; Hayashi, M; Hohl, RJ; Lee, CK; Schlueter, A; Strauss, RG, 2002) |
| " daily for 4 days, ifosfamide 1500 mg mixed with equal dosing of mesna continuously infused i." | 2.70 | DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL). ( Coleman, M; Kaufman, TP; Leonard, J; Shuster, MW, 2001) |
| "A fast metabolism of TRO with a half-life of about 1 h was observed." | 2.70 | New insights into the clinical pharmacokinetics of trofosfamide. ( Brinker, A; Brüggemann, SK; Kisro, J; Letsch, C; Wagner, T, 2002) |
| " In older patients (> 60 years) the dosage of idarubicin and ifosfamide was reduced to 75% in the initial cycle." | 2.69 | DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. ( Borchmann, P; Diehl, V; Engert, A; Münch, R; Reiser, M; Schnell, R; Straub, G; Ubelacker, R; Wilhelm, M; Wörmann, B, 1998) |
| "Evaluate response, duration of response, and toxicity of paclitaxel in combination with other drugs known to be effective in non-Hodgkin's lymphoma (NHL)." | 2.69 | Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. ( Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, A; Rodriguez, J; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A, 1999) |
| " There were no toxic deaths." | 2.69 | Epic as an effective, low toxicity salvage therapy for patients with poor risk lymphoma prior to beam high dose chemotherapy and peripheral blood progenitor cell transplantation. ( Cavenagh, JD; Eden, AG; Hughes, A; Kelsey, SM; Lamont, A; McBride, NC; Mills, MJ; Newland, AC; Ward, MC, 1999) |
| "Treatment of Hodgkin's disease (HD) and non-Hodgkin lymphomas (NHL) is still unsatisfactory in patients resistant to primary therapy or those with early relapses." | 2.69 | [Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells]. ( Adam, Z; Hájek, R; Hejlová, N; Klabusay, M; Korístek, Z; Krahulcová, E; Král, Z; Mayer, J; Müllerová, I; Navrátil, M; Penka, M; Tomíska, M; Vásová, I; Vodvárka, P; Vorlícek, J, 1998) |
| " In parallel, patients with solid tumors or non-Hodgkin's lymphomas (n = 28) treated with etoposide (500 mg/m2), ifosfamide (1500 mg/m2) and cisplatin (150 mg/m2) and identical dosing of G-CSF were analyzed." | 2.68 | Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF. ( Engelhardt, M; Henschler, R; Lange, W; Mertelsmann, R; Waller, C; Winkler, J, 1997) |
| "Therapy for group non-B patients (lymphoblastic lymphoma and pleomorphic T-cell lymphoma [PTCL]) consisted of a Berlin-Frankfurt-Münster (BFM) acute lymphoblastic leukemia protocol, including cranial irradiation for advanced stage." | 2.68 | Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. ( Gadner, H; Henze, G; Ludwig, WD; Müller-Weihrich, S; Parwaresch, R; Reiter, A; Riehm, H; Sauter, S; Schrappe, M; Sykora, KW, 1995) |
| " However on multivariate analysis only the presence of bulky disease and of B symptoms were independent adverse factors for response and for survival." | 2.67 | EPIC: an effective low toxicity regimen for relapsing lymphoma. ( Ashley, S; Catovsky, D; Cunningham, D; Gore, ME; Hickish, T; Mansi, J; Nicolson, V; Roldan, A; Smith, IE, 1993) |
| "Ifosfamide is an alkylating agent with a broad spectrum of activity in solid tumors and hematological malignancies." | 2.42 | Ifosfamide in hematological malignancies of adults. ( Elice, F; Rodeghiero, F, 2003) |
| "Ifosfamide has been used extensively for the treatment of patients with non-Hodgkin's lymphoma (NHL)." | 2.39 | Ifosfamide in the treatment of non-Hodgkin's lymphoma. ( Pohlman, B, 1996) |
| " Sequential dosing protocols, administration of high-dose chemotherapy with peripheral blood progenitor cell support, and other approaches, possibly combining current treatment options, may be necessary to further improve the long-term survival of patients with relapsed NHL." | 2.39 | Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma. ( Vose, JM, 1996) |
| "Thoracic and abdominal irradiation for Hodgkin's disease was performed concomitantly with chemotherapy for the non-Hodgkin's lymphoma." | 2.38 | Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease. ( Bergeron, C; Chatel, M; Darcel, F; Edan, C; Faivre, J; Jouan, H; Le Moine, P; Le Prise-Fleury, E; Patte, C; Tass, P, 1993) |
| "Ifosfamide has been shown to have significant single-agent activity against non-Hodgkin's lymphoma and its use in various combinations produces response rates of 20% to 83% in patients with refractory or relapsing disease." | 2.38 | New perspectives in the treatment of non-Hodgkin's lymphoma. ( Goss, PE, 1992) |
| " The predictive capability of a published nomogram is restricted by differences in dosage regimens and encephalopathic classifications." | 2.38 | Ifosfamide-induced neurotoxicity: a case report and review of the literature. ( Eaton, VE; Miller, LJ, 1992) |
| "As salvage therapy in non-Hodgkin's lymphoma (NHL), IMV-Bleo (ifosfamide, methotrexate, etoposide, bleomycin) produced a complete remission (CR) rate of 41% and seemed to be particularly effective in patients with suboptimal response to first-line treatment." | 2.38 | European experience with ifosfamide in lymphomas. ( Diehl, V; Schaadt, M; von Kalle, AK, 1989) |
| " The purpose of this study was to explore the efficacy and safety of programmed cell death 1 (PD-1) blockade combined with ICE regimen (P-ICE) in the treatment of R/R DLBCL patients." | 1.91 | PD-1 blockade combined with ICE regimen in relapsed/refractory diffuse large B-cell lymphoma. ( Bai, B; Gao, Y; He, Y; Huang, C; Huang, H; Ping, L; Shi, L; Wang, X, 2023) |
| " Dosing was modified for elderly patients." | 1.72 | Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma. ( Borawska, A; Chełstowska, M; Dąbrowska-Iwanicka, A; Domańska-Czyż, K; Druzd-Sitek, A; Giebel, S; Knopińska-Posłuszny, W; Konecki, R; Kumiega, B; Lange, A; Malenda, A; Michalski, W; Mordak-Domagała, M; Najda, J; Osowiecki, M; Ostrowska, B; Paszkiewicz-Kozik, E; Pluta, A; Popławska, L; Romejko-Jarosińska, J; Rymkiewicz, G; Świerkowska, M; Szpila, T; Szymański, M; Targoński, Ł; Taszner, M; Walewski, J; Zaucha, JM, 2022) |
| "Of the classical Hodgkin lymphoma patients, the ORR were 72." | 1.56 | Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study. ( Li, J; Liu, Z; Mi, M; Wang, Y; Zhang, C; Zhang, L, 2020) |
| "The extrapolation of the Calvert formula has utility in calculating the CBDCA dosage for DeVIC ± R therapy, and therapeutic efficacy was increased by maintaining the AUC of CBDCA at ≥4." | 1.43 | Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin ( Ando, M; Ando, Y; Emi, N; Hayashi, T; Inaguma, Y; Ito, K; Okamoto, A; Okamoto, M; Tomono, A; Tsuge, M; Yamada, S, 2016) |
| "Two patients with Hodgkin's lymphoma and two with non-Hodgkin's lymphoma who were undergoing stem cell therapy were studied." | 1.43 | Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. ( Arima, N; Fukunaga, A; Hyuga, M; Iwasaki, M; Kishimoto, W; Maesako, Y; Nakae, Y, 2016) |
| " Primary therapies were divided into four groups: radiotherapy alone, moderately dosed COPP/ABVD-like chemotherapies for intermediate and advanced stages and BEACOPP escalated." | 1.37 | Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. ( Diehl, V; Engert, A; Franklin, J; Hasenclever, D; Josting, A; Loeffler, M; Scholz, M, 2011) |
| "Patients with hematologic or solid tumors who underwent conditioning regimen were asked to score mucositis severity daily from the first day to the tenth day of reinfusion." | 1.35 | Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation. ( Arpaci, F; Ataergin, S; Kilic, S; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M, 2009) |
| "Of the 13 cases, 5 were Hodgkin's disease (HD), and 8 were non-Hodgkin's lymphoma (NHL)." | 1.33 | [Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma]. ( Ling, JY; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006) |
| "Seventeen patients had non-Hodgkin lymphoma (NHL) and 13 patients had Hodgkin disease (HD)." | 1.33 | IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. ( Abali, H; Barista, I; Demirkazik, F; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekin, F; Tekuzman, G; Turker, A; Uner, A, 2005) |
| "Sites of relapse were designated as old (involved prior to HDCT) or new (previously uninvolved)." | 1.30 | High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma: pattern of failure and implications for involved-field radiotherapy. ( Hallahan, D; Mundt, AJ; Williams, SF, 1997) |
| "Twelve patients with Hodgkin's disease (HD) and 38 patients with non-Hodgkin's lymphoma (NHL) were mobilized with MIME/G-CSF." | 1.30 | Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. ( Aurlien, E; Holte, H; Jakobsen, E; Kvalheim, G; Kvaløy, S; Pharo, A; Smeland, EB, 1998) |
| "Epirubicin (Epi) was favored because of its low hemato- and cardiotoxicity [2]." | 1.29 | IEVM chemotherapy with rhGM-CSF support for aggressive non-Hodgkin's lymphomas: a pilot study. ( Gerhartz, HH; Walther, J; Wilmanns, W, 1993) |
| " The overall response rate of 41% might be improved by increased dosage and growth factor support." | 1.29 | Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma. ( Heinz, R; Hopfinger, G; Koller, E; Pittermann, E; Schneider, B, 1995) |
| "Eight patients had low-grade non-Hodgkin's lymphoma (NHL), 28 had high-grade NHL, and 11 patients had Hodgkin's disease." | 1.28 | Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas. ( Anders, CH; Moritz, T; Nagel-Hiemke, M; Niederle, N; Nowrousian, MR; Schmidt, CG; Seeber, S, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (7.77) | 18.7374 |
| 1990's | 90 (46.63) | 18.2507 |
| 2000's | 63 (32.64) | 29.6817 |
| 2010's | 18 (9.33) | 24.3611 |
| 2020's | 7 (3.63) | 2.80 |
| Authors | Studies |
|---|---|
| Paszkiewicz-Kozik, E | 1 |
| Michalski, W | 1 |
| Taszner, M | 1 |
| Mordak-Domagała, M | 1 |
| Romejko-Jarosińska, J | 1 |
| Knopińska-Posłuszny, W | 1 |
| Najda, J | 1 |
| Borawska, A | 1 |
| Chełstowska, M | 1 |
| Świerkowska, M | 1 |
| Dąbrowska-Iwanicka, A | 1 |
| Malenda, A | 1 |
| Druzd-Sitek, A | 1 |
| Konecki, R | 1 |
| Kumiega, B | 1 |
| Osowiecki, M | 1 |
| Ostrowska, B | 1 |
| Szpila, T | 1 |
| Szymański, M | 1 |
| Targoński, Ł | 1 |
| Domańska-Czyż, K | 1 |
| Popławska, L | 1 |
| Giebel, S | 2 |
| Lange, A | 1 |
| Pluta, A | 1 |
| Zaucha, JM | 1 |
| Rymkiewicz, G | 1 |
| Walewski, J | 1 |
| Pavlovsky, M | 1 |
| Cubero, D | 1 |
| Agreda-Vásquez, GP | 1 |
| Enrico, A | 1 |
| Mela-Osorio, MJ | 1 |
| San Sebastián, JA | 1 |
| Fogliatto, L | 1 |
| Ovilla, R | 1 |
| Avendano, O | 1 |
| Machnicki, G | 1 |
| Barreyro, P | 1 |
| Trufelli, D | 1 |
| Villanova, P | 1 |
| Ping, L | 1 |
| Gao, Y | 1 |
| He, Y | 1 |
| Bai, B | 1 |
| Huang, C | 1 |
| Shi, L | 1 |
| Wang, X | 1 |
| Huang, H | 1 |
| Lin, LH | 1 |
| Ghasemi, M | 1 |
| Burke, SM | 1 |
| Mavis, CK | 1 |
| Nichols, JR | 1 |
| Torka, P | 1 |
| Mager, DE | 1 |
| Hernandez-Ilizaliturri, FJ | 1 |
| Goey, AKL | 1 |
| Behera, G | 1 |
| Purkait, S | 1 |
| Patra, S | 1 |
| Sasmal, PK | 1 |
| Majumdar, SKD | 1 |
| Das, DK | 1 |
| Naik, S | 1 |
| Singh, PK | 1 |
| Dangien, A | 1 |
| Ram-Wolff, C | 1 |
| Brice, P | 1 |
| Battistella, M | 1 |
| Roelens, M | 1 |
| Moins-Teisserenc, H | 1 |
| Peffault de Latour, R | 1 |
| Mourah, S | 1 |
| Bouaziz, JD | 1 |
| Lebbé, C | 1 |
| Bagot, M | 1 |
| de Masson, A | 1 |
| Mi, M | 1 |
| Zhang, C | 1 |
| Liu, Z | 1 |
| Wang, Y | 1 |
| Li, J | 1 |
| Zhang, L | 1 |
| Kim, SK | 1 |
| Song, MK | 1 |
| Chung, JS | 1 |
| Shin, HJ | 1 |
| Sun, H | 1 |
| Savage, KJ | 1 |
| Karsan, A | 1 |
| Slack, GW | 1 |
| Gascoyne, RD | 1 |
| Toze, CL | 1 |
| Sehn, LH | 1 |
| Abou Mourad, Y | 1 |
| Barnett, MJ | 1 |
| Broady, RC | 1 |
| Connors, JM | 1 |
| Forrest, DL | 1 |
| Gerrie, AS | 1 |
| Hogge, DE | 1 |
| Narayanan, S | 1 |
| Nevill, TJ | 1 |
| Nantel, SH | 1 |
| Power, MM | 1 |
| Sutherland, HJ | 1 |
| Villa, D | 1 |
| Shepherd, JD | 1 |
| Song, KW | 1 |
| Esbah, O | 1 |
| Tekgündüz, E | 1 |
| Şirinoğlu Demiriz, I | 1 |
| Civriz Bozdağ, S | 1 |
| Kaya, A | 1 |
| Tetik, A | 1 |
| Kayıkçı, Ö | 1 |
| Durgun, G | 1 |
| Kocubaba, Ş | 1 |
| Altuntaş, F | 1 |
| Park, S | 1 |
| Hong, J | 1 |
| Hwang, I | 1 |
| Ahn, JY | 1 |
| Cho, EY | 1 |
| Park, J | 1 |
| Cho, EK | 1 |
| Shin, DB | 1 |
| Lee, JH | 1 |
| Landsburg, DJ | 1 |
| Petrich, AM | 1 |
| Abramson, JS | 1 |
| Sohani, AR | 1 |
| Press, O | 1 |
| Cassaday, R | 1 |
| Chavez, JC | 1 |
| Song, K | 1 |
| Zelenetz, AD | 6 |
| Gandhi, M | 1 |
| Shah, N | 1 |
| Fenske, TS | 2 |
| Jaso, J | 1 |
| Medeiros, LJ | 1 |
| Yang, DT | 1 |
| Nabhan, C | 1 |
| Schorb, E | 1 |
| Finke, J | 1 |
| Ferreri, AJ | 1 |
| Ihorst, G | 1 |
| Mikesch, K | 1 |
| Kasenda, B | 1 |
| Fritsch, K | 1 |
| Fricker, H | 1 |
| Burger, E | 1 |
| Grishina, O | 1 |
| Valk, E | 1 |
| Zucca, E | 1 |
| Illerhaus, G | 1 |
| Tomono, A | 1 |
| Ito, K | 1 |
| Hayashi, T | 1 |
| Ando, M | 1 |
| Ando, Y | 1 |
| Tsuge, M | 1 |
| Okamoto, A | 1 |
| Inaguma, Y | 1 |
| Okamoto, M | 4 |
| Emi, N | 1 |
| Yamada, S | 1 |
| Fukunaga, A | 1 |
| Hyuga, M | 1 |
| Iwasaki, M | 1 |
| Nakae, Y | 1 |
| Kishimoto, W | 1 |
| Maesako, Y | 1 |
| Arima, N | 1 |
| Dhakal, B | 1 |
| Veltri, LW | 1 |
| Eastwood, D | 1 |
| Craig, MD | 1 |
| Cumpston, A | 1 |
| Shillingburg, A | 1 |
| Esselman, J | 1 |
| Watkins, K | 1 |
| Pasquini, MC | 1 |
| D'Souza, A | 1 |
| Hari, P | 1 |
| Kanate, AS | 1 |
| Hamadani, M | 1 |
| Aurer, I | 2 |
| Mitrović, Z | 1 |
| Nemet, D | 2 |
| Radman, I | 2 |
| Sertić, D | 2 |
| Serventi-Seiwerth, R | 1 |
| Stern-Padovan, R | 1 |
| Santek, F | 1 |
| Nola, M | 1 |
| Mrsić, M | 2 |
| Labar, B | 2 |
| Liu, XM | 1 |
| Wang, HQ | 1 |
| Zhang, HL | 1 |
| Qiu, LH | 1 |
| Li, W | 1 |
| Li, LF | 1 |
| Cui, XZ | 1 |
| Liu, PF | 1 |
| Hao, XS | 1 |
| Ozturk, M | 1 |
| Komurcu, S | 1 |
| Kilic, S | 1 |
| Ozet, A | 1 |
| Arpaci, F | 1 |
| Ozturk, B | 1 |
| Kuzhan, O | 1 |
| Ataergin, S | 1 |
| Ridola, V | 1 |
| Fawaz, O | 1 |
| Aubier, F | 1 |
| Bergeron, C | 2 |
| de Vathaire, F | 1 |
| Pichon, F | 1 |
| Orbach, D | 1 |
| Gentet, JC | 1 |
| Schmitt, C | 1 |
| Dufour, C | 1 |
| Oberlin, O | 1 |
| Lazar, AD | 1 |
| Shpilberg, O | 1 |
| Shaklai, M | 1 |
| Bairey, O | 1 |
| Hong, SJ | 1 |
| Kim, JS | 2 |
| Chang, JH | 1 |
| Kim, KM | 1 |
| Kim, SJ | 1 |
| Lee, HW | 1 |
| Cheong, JW | 1 |
| Lee, ST | 1 |
| Min, YH | 1 |
| Nishimori, H | 1 |
| Fujii, N | 1 |
| Maeda, Y | 1 |
| Matsuoka, K | 1 |
| Takenaka, K | 1 |
| Shinagawa, K | 1 |
| Ikeda, K | 1 |
| Matsuo, K | 1 |
| Harada, M | 1 |
| Tanimoto, M | 1 |
| Fridrik, MA | 2 |
| Hausmaninger, H | 2 |
| Lang, A | 1 |
| Drach, J | 1 |
| Krieger, O | 1 |
| Geissler, D | 1 |
| Michlmayr, G | 1 |
| Ulsperger, E | 1 |
| Chott, A | 2 |
| Oberaigner, W | 1 |
| Greil, R | 1 |
| Park, BB | 1 |
| Kim, WS | 1 |
| Eom, HS | 1 |
| Lee, YY | 1 |
| Oh, SJ | 1 |
| Lee, DH | 1 |
| Suh, C | 1 |
| Dincol, D | 2 |
| Buyukcelik, A | 1 |
| Dogan, M | 1 |
| Akbulut, H | 2 |
| Samur, M | 1 |
| Demirkazik, A | 2 |
| Senler, FC | 1 |
| Onur, H | 1 |
| Icli, F | 2 |
| Dührsen, U | 1 |
| Hüttmann, A | 1 |
| Jöckel, KH | 1 |
| Müller, S | 2 |
| Sandlund, JT | 1 |
| Pui, CH | 1 |
| Mahmoud, H | 1 |
| Zhou, Y | 1 |
| Lowe, E | 1 |
| Kaste, S | 1 |
| Kun, LE | 1 |
| Krasin, MJ | 1 |
| Onciu, M | 1 |
| Behm, FG | 1 |
| Ribeiro, RC | 1 |
| Razzouk, BI | 1 |
| Howard, SC | 1 |
| Metzger, ML | 1 |
| Hale, GA | 1 |
| Rencher, R | 1 |
| Graham, K | 1 |
| Hudson, MM | 1 |
| Scholz, M | 1 |
| Engert, A | 3 |
| Franklin, J | 1 |
| Josting, A | 1 |
| Diehl, V | 4 |
| Hasenclever, D | 1 |
| Loeffler, M | 2 |
| George, B | 1 |
| Benson, W | 2 |
| Hertzberg, MS | 2 |
| Birnbaum, T | 2 |
| Stadler, EA | 1 |
| von Baumgarten, L | 2 |
| Straube, A | 2 |
| Ong, P | 1 |
| Greulich, S | 1 |
| Schumm, J | 1 |
| Backes, M | 1 |
| Kaufmann, M | 1 |
| Bode-Erdmann, S | 1 |
| Ott, G | 1 |
| Hebart, H | 1 |
| Mahrholdt, H | 1 |
| Bochmann, K | 1 |
| Zinzani, PL | 2 |
| Tani, M | 1 |
| Molinari, AL | 1 |
| Stefoni, V | 1 |
| Zuffa, E | 1 |
| Alinari, L | 1 |
| Gabriele, A | 1 |
| Bonifazi, F | 1 |
| Salvucci, M | 1 |
| Tura, S | 1 |
| Baccarani, M | 1 |
| Lee, CK | 1 |
| de Magalhaes-Silverman, M | 1 |
| Hayashi, M | 1 |
| Schlueter, A | 1 |
| Strauss, RG | 1 |
| Hohl, RJ | 1 |
| Gingrich, RD | 1 |
| Sawada, M | 1 |
| Tsurumi, H | 1 |
| Yamada, T | 1 |
| Hara, T | 1 |
| Fukuno, K | 1 |
| Goto, H | 1 |
| Shimizu, M | 1 |
| Kasahara, S | 1 |
| Yoshikawa, T | 1 |
| Kanemura, N | 1 |
| Oyama, M | 1 |
| Takami, T | 1 |
| Moriwaki, H | 1 |
| Salar, A | 1 |
| Martino, R | 1 |
| Perea, G | 1 |
| Ribera, JM | 1 |
| López-Guillermo, A | 3 |
| Guardia, R | 1 |
| Escoda, L | 1 |
| Altés, A | 1 |
| Sierra, J | 1 |
| Montserrat, E | 3 |
| Duraković, N | 1 |
| Zupancić-Salek, S | 1 |
| Kovacević-Metelko, J | 1 |
| Bogdanić, V | 1 |
| Mikulić, M | 1 |
| Emmanouilides, C | 1 |
| Lill, M | 1 |
| Telatar, M | 1 |
| Rosenfelt, F | 1 |
| Grody, W | 1 |
| Territo, M | 1 |
| Rosen, P | 1 |
| Brinker, A | 1 |
| Kisro, J | 1 |
| Letsch, C | 1 |
| Brüggemann, SK | 1 |
| Wagner, T | 1 |
| Mottl, H | 1 |
| Bajciova, V | 1 |
| Nemec, J | 1 |
| Al Shemmari, S | 1 |
| Al Awadi, S | 1 |
| Arellano-Rodrigo, E | 1 |
| Bessell, EM | 1 |
| Nomdedeu, B | 1 |
| Graus, F | 1 |
| Sneller, V | 2 |
| Armitage, J | 1 |
| Hamlin, P | 1 |
| Kewalramani, T | 2 |
| Yahalom, J | 4 |
| Nimer, S | 1 |
| Moskowitz, CH | 5 |
| Crombie, C | 1 |
| Taper, J | 1 |
| Gottlieb, D | 1 |
| Bradstock, KF | 1 |
| Vose, J | 1 |
| Mead, G | 1 |
| Woodcock, J | 1 |
| Young, C | 1 |
| Rodeghiero, F | 1 |
| Elice, F | 1 |
| Davidson, KL | 1 |
| Devaney, MB | 1 |
| Tighe, JE | 1 |
| Rogers, SY | 1 |
| Dunlop, DJ | 1 |
| Mackie, MJ | 1 |
| Thomas, RV | 1 |
| Johnson, PR | 1 |
| Gisselbrecht, C | 2 |
| Mounier, N | 1 |
| Van Besien, K | 2 |
| Mehra, R | 2 |
| Wadehra, N | 1 |
| Stock, W | 1 |
| Khouri, I | 2 |
| Giralt, S | 4 |
| Devine, S | 1 |
| Wickrema, A | 1 |
| Peace, D | 1 |
| Sosman, J | 1 |
| Gajewski, J | 2 |
| Champlin, R | 3 |
| Pocali, B | 1 |
| De Simone, M | 1 |
| Annunziata, M | 1 |
| Palmieri, S | 1 |
| D'Amico, MR | 1 |
| Copia, C | 1 |
| Viola, A | 1 |
| Mele, G | 1 |
| Schiavone, EM | 1 |
| Ferrara, F | 1 |
| Musolino, A | 1 |
| Perrone, MA | 1 |
| Michiara, M | 1 |
| Delnevo, D | 1 |
| Franciosi, V | 1 |
| Di Blasio, B | 1 |
| Ceci, G | 1 |
| Camisa, R | 1 |
| Ardizzoni, A | 1 |
| Cocconi, G | 1 |
| Zhou, SY | 1 |
| Shi, YK | 1 |
| He, XH | 1 |
| Zhang, P | 1 |
| Dong, M | 1 |
| Huang, DZ | 1 |
| Yang, JL | 1 |
| Zhang, CG | 1 |
| Liu, P | 1 |
| Yang, S | 1 |
| Feng, FY | 1 |
| Abali, H | 2 |
| Oyan, B | 2 |
| Koc, Y | 2 |
| Kars, A | 3 |
| Barista, I | 2 |
| Uner, A | 1 |
| Turker, A | 2 |
| Demirkazik, F | 1 |
| Tekin, F | 1 |
| Tekuzman, G | 3 |
| Kansu, E | 2 |
| Chamorey, E | 1 |
| Gressin, R | 1 |
| Peyrade, F | 1 |
| Rossi, JF | 1 |
| Lepeu, G | 1 |
| Foussard, C | 1 |
| Harrousseau, JL | 1 |
| Fabbro, M | 1 |
| Richard, B | 1 |
| Delwail, V | 1 |
| Maisonneuve, H | 1 |
| Vilque, JP | 1 |
| Thyss, A | 1 |
| Ozdemir, E | 1 |
| Clavio, M | 1 |
| Garrone, A | 1 |
| Pierri, I | 1 |
| Michelis, GL | 1 |
| Balocco, M | 1 |
| Albarello, A | 1 |
| Varaldo, R | 1 |
| Canepa, P | 1 |
| Miglino, M | 1 |
| Ballerini, F | 1 |
| Canepa, L | 1 |
| Gobbi, M | 1 |
| Pereira, J | 1 |
| Bellesso, M | 1 |
| Pracchia, LF | 1 |
| Neto, AE | 1 |
| Beitler, B | 1 |
| de Almeida Macedo, MC | 1 |
| Dias, LC | 1 |
| Dorlhiac-Llacer, PE | 1 |
| Dulley, FL | 1 |
| Chamone, D | 1 |
| Zhen, ZJ | 1 |
| Sun, XF | 1 |
| Xia, Y | 1 |
| Wang, ZH | 1 |
| Ling, JY | 1 |
| Li, HH | 1 |
| Wu, XX | 1 |
| Wang, QS | 1 |
| Zhao, Y | 1 |
| Bo, J | 1 |
| Wang, SH | 1 |
| DA, WM | 1 |
| Yu, L | 1 |
| Ford, CD | 1 |
| Gabor, F | 1 |
| Morgan, R | 1 |
| Dabbas, B | 1 |
| Hosing, C | 1 |
| Saliba, RM | 1 |
| Körbling, M | 2 |
| Acholonu, S | 1 |
| McMannis, J | 1 |
| Anderlini, P | 2 |
| De Lima, M | 1 |
| Okoroji, GJ | 1 |
| Couriel, DR | 1 |
| Khouri, IF | 1 |
| Donato, ML | 2 |
| Bo, LJ | 1 |
| Liang, AB | 1 |
| Liu, B | 1 |
| Chen, YH | 1 |
| Wang, F | 1 |
| Jin, XP | 1 |
| Sugimoto, T | 1 |
| Matano, S | 2 |
| Nishijima, H | 1 |
| Kakuta, K | 1 |
| Inamura, K | 1 |
| Okamura, T | 1 |
| Munemoto, S | 1 |
| Satoh, S | 1 |
| Bishton, MJ | 1 |
| Lush, RJ | 1 |
| Byrne, JL | 1 |
| Russell, NH | 1 |
| Shaw, BE | 1 |
| Haynes, AP | 1 |
| Schütt, P | 1 |
| Passon, J | 1 |
| Ebeling, P | 1 |
| Welt, A | 1 |
| Metz, K | 1 |
| Moritz, T | 2 |
| Seeber, S | 2 |
| Nowrousian, MR | 3 |
| Nair, R | 1 |
| Prabhash, K | 1 |
| Sengar, M | 1 |
| Bakshi, A | 1 |
| Gujral, S | 1 |
| Gupta, S | 1 |
| Parikh, P | 1 |
| Hamlin, PA | 1 |
| Gabrilove, J | 1 |
| Bertino, JR | 3 |
| Portlock, CS | 4 |
| Straus, DJ | 2 |
| Gencarelli, AN | 1 |
| Nimer, SD | 4 |
| Russell, N | 2 |
| Mesters, R | 1 |
| Schubert, J | 1 |
| Boogaerts, M | 1 |
| Johnsen, HE | 1 |
| Canizo, CD | 1 |
| Baker, N | 1 |
| Barker, P | 1 |
| Skacel, T | 1 |
| Schmitz, N | 2 |
| Urün, Y | 1 |
| Oksüzoğlu, B | 1 |
| Budakoğlu, B | 1 |
| Yildirim, N | 1 |
| Güler, T | 1 |
| Ozet, G | 1 |
| Zengin, N | 1 |
| Karaoğuz, H | 1 |
| Cay, F | 1 |
| Arican, A | 1 |
| Maruyama, F | 3 |
| Ezaki, K | 2 |
| Miyazaki, H | 3 |
| Wakita, M | 2 |
| Nomura, T | 2 |
| Tsuzuki, M | 2 |
| Kojima, H | 2 |
| Sobue, R | 3 |
| Matsui, T | 4 |
| Ben-Dayan, D | 1 |
| Mittelman, M | 1 |
| Floru, S | 1 |
| Djaldetti, M | 1 |
| Hirano, M | 3 |
| Siegert, W | 5 |
| Nerl, C | 1 |
| Engelhard, M | 6 |
| Brittinger, G | 5 |
| Tiemann, M | 2 |
| Parwaresch, R | 2 |
| Heinz, R | 4 |
| Huhn, D | 5 |
| De Lena, M | 2 |
| Ditonno, P | 1 |
| Lorusso, V | 2 |
| Brandi, M | 1 |
| Timurian, A | 1 |
| Marzullo, F | 1 |
| Ventrella, V | 1 |
| Pellecchia, A | 1 |
| Haim, N | 4 |
| Ben-Shahar, M | 4 |
| Epelbaum, R | 4 |
| Martínez, C | 1 |
| Mateu, R | 1 |
| Sureda, A | 1 |
| Brunet, S | 1 |
| Amill, B | 1 |
| Madoz, P | 1 |
| Portos, JM | 1 |
| Subirà, M | 1 |
| García-López, J | 1 |
| Domingo-Albós, A | 1 |
| Dreger, P | 1 |
| Klöss, M | 1 |
| Petersen, B | 1 |
| Haferlach, T | 1 |
| Löffler, H | 1 |
| Hopfinger, G | 1 |
| Koller, E | 1 |
| Schneider, B | 1 |
| Pittermann, E | 1 |
| Rodriguez, MA | 8 |
| Cabanillas, FC | 1 |
| Velasquez, W | 1 |
| Hagemeister, FB | 6 |
| McLaughlin, P | 6 |
| Swan, F | 1 |
| Romaguera, JE | 5 |
| Cairo, MS | 1 |
| Eghbali, H | 1 |
| Catry-Thomas, I | 1 |
| Soubeyran, P | 1 |
| Bonnel, C | 1 |
| Hoerni, B | 1 |
| Takeshima, M | 1 |
| Nakamura, S | 1 |
| Mochizuki, Y | 1 |
| Hattori, N | 1 |
| Kaya, H | 1 |
| Otake, S | 1 |
| Okabe, Y | 1 |
| Okumura, H | 1 |
| Yoshida, T | 1 |
| Fields, KK | 1 |
| Elfenbein, GJ | 1 |
| Lazarus, HM | 1 |
| Cooper, BW | 1 |
| Perkins, JB | 1 |
| Creger, RJ | 1 |
| Ballester, OF | 1 |
| Hiemenz, JH | 1 |
| Janssen, WE | 1 |
| Zorsky, PE | 1 |
| Reiter, A | 2 |
| Schrappe, M | 2 |
| Henze, G | 2 |
| Müller-Weihrich, S | 2 |
| Sauter, S | 1 |
| Sykora, KW | 1 |
| Ludwig, WD | 2 |
| Gadner, H | 1 |
| Riehm, H | 2 |
| Mateu, J | 1 |
| Alzamora, M | 1 |
| Franco, M | 1 |
| Buisán, MJ | 1 |
| Abate, G | 1 |
| Tafuto, S | 1 |
| Marcacci, G | 1 |
| Corazzelli, G | 1 |
| Fimiani, P | 1 |
| Monda, VM | 1 |
| Gailli, E | 1 |
| D'Andrea, P | 1 |
| Iaccarino, G | 1 |
| Buzzoni, R | 1 |
| Colleoni, M | 1 |
| Nelli, P | 1 |
| Nolè, F | 1 |
| Bajetta, E | 1 |
| Ino, T | 2 |
| Köppler, H | 2 |
| Pflüger, KH | 2 |
| Eschenbach, I | 2 |
| Pfab, R | 2 |
| Birkmann, J | 1 |
| Zeller, W | 2 |
| Holle, R | 1 |
| Steinhauer, UE | 1 |
| Gropp, C | 2 |
| Oehl, S | 2 |
| Prescott, RJ | 1 |
| Leonard, RC | 1 |
| Hickish, T | 1 |
| Roldan, A | 1 |
| Cunningham, D | 1 |
| Mansi, J | 1 |
| Ashley, S | 1 |
| Nicolson, V | 1 |
| Gore, ME | 1 |
| Catovsky, D | 1 |
| Smith, IE | 1 |
| Le Moine, P | 1 |
| Le Prise-Fleury, E | 1 |
| Jouan, H | 1 |
| Tass, P | 1 |
| Darcel, F | 1 |
| Chatel, M | 1 |
| Edan, C | 1 |
| Patte, C | 1 |
| Faivre, J | 1 |
| Walther, J | 1 |
| Wilmanns, W | 2 |
| Gerhartz, HH | 3 |
| Linkesch, W | 1 |
| Stöger, M | 1 |
| Sill, H | 1 |
| Neubauer, M | 1 |
| Seewann, HL | 1 |
| Klocker, J | 1 |
| Haidinger, R | 1 |
| Schiller, L | 1 |
| Pont, J | 1 |
| Raudaschl, G | 1 |
| Falk, M | 1 |
| Radaszkiewicz, T | 1 |
| Cheng, AL | 1 |
| Goss, P | 1 |
| Shepherd, F | 1 |
| Scott, JG | 2 |
| Baker, M | 1 |
| Sutton, D | 2 |
| Sutcliffe, S | 2 |
| Weintraub, M | 1 |
| Adde, MA | 1 |
| Venzon, DJ | 1 |
| Shad, AT | 1 |
| Horak, ID | 2 |
| Neely, JE | 1 |
| Seibel, NL | 1 |
| Gootenberg, J | 2 |
| Arndt, C | 2 |
| Nieder, ML | 1 |
| Magrath, IT | 1 |
| Magrath, I | 2 |
| Adde, M | 2 |
| Shad, A | 1 |
| Venzon, D | 1 |
| Seibel, N | 1 |
| Neely, J | 1 |
| Nieder, M | 1 |
| Jaffe, E | 1 |
| Wittes, RA | 1 |
| Stamatoullas, A | 1 |
| Fruchart, C | 1 |
| Bastit, D | 1 |
| Boulet, D | 1 |
| Moncondult, M | 1 |
| Piguet, H | 1 |
| Tilly, H | 2 |
| Pettengell, R | 1 |
| Radford, JA | 1 |
| Morgenstern, GR | 1 |
| Scarffe, JH | 1 |
| Harris, M | 1 |
| Woll, PJ | 1 |
| Deakin, DP | 1 |
| Ryder, D | 1 |
| Wilkinson, PM | 1 |
| Crowther, D | 1 |
| Enblad, G | 2 |
| Hagberg, H | 2 |
| Glimelius, B | 2 |
| Wong, ET | 1 |
| O'Brien, JP | 2 |
| DeAngelis, LM | 1 |
| Pohlman, B | 1 |
| Vose, JM | 1 |
| Coiffier, B | 2 |
| Voûte, PA | 1 |
| van den Berg, H | 1 |
| Behrendt, H | 1 |
| Michiels, E | 1 |
| de Kraker, J | 1 |
| Schnell, R | 2 |
| Küpper, F | 1 |
| Reiser, M | 2 |
| Wilhelm, M | 2 |
| Lathan, B | 1 |
| Baltes-Engler, S | 1 |
| Winterhalter, B | 1 |
| Scheulen, ME | 1 |
| Dederichs, B | 1 |
| Tesch, H | 1 |
| Wörmann, B | 2 |
| Engelhardt, M | 1 |
| Winkler, J | 1 |
| Waller, C | 1 |
| Lange, W | 1 |
| Mertelsmann, R | 1 |
| Henschler, R | 1 |
| Mundt, AJ | 1 |
| Williams, SF | 1 |
| Hallahan, D | 1 |
| Rodriguez-Monge, EJ | 1 |
| Cabanillas, F | 9 |
| Faraggi, D | 1 |
| Tsuri-Etzioni, A | 1 |
| Leviov, M | 1 |
| Garay, G | 1 |
| Dupont, J | 1 |
| Dragosky, M | 1 |
| Nucifora, E | 1 |
| Cacchione, R | 1 |
| Schnidrig, P | 1 |
| Fernández, J | 1 |
| Riveros, D | 1 |
| Noviello, V | 1 |
| Bèguelin, R | 1 |
| Campestri, R | 1 |
| Albera, C | 1 |
| Nicastro, M | 1 |
| Triguboff, E | 1 |
| Aydogdu, I | 1 |
| Koc, H | 1 |
| Ilhan, O | 1 |
| Gurman, G | 1 |
| Akan, H | 1 |
| Beksac, M | 1 |
| Konuk, N | 1 |
| Uysal, A | 1 |
| Ozerol, E | 1 |
| Kleiner, S | 1 |
| Kirsch, A | 1 |
| Schwaner, I | 1 |
| Kingreen, D | 1 |
| Schwella, N | 1 |
| Aurlien, E | 1 |
| Holte, H | 1 |
| Pharo, A | 1 |
| Kvaløy, S | 1 |
| Jakobsen, E | 1 |
| Smeland, EB | 1 |
| Kvalheim, G | 1 |
| Rodriguez-Diaz Pavón, J | 1 |
| Dong, K | 1 |
| Moon, T | 1 |
| García-Conde, J | 1 |
| Alvarez-Carmona, AM | 1 |
| León, P | 1 |
| Maldonado, J | 1 |
| Alcalá, A | 1 |
| Zubizarreta, A | 1 |
| Sancho-Tello, R | 1 |
| Carbonell, F | 1 |
| Contreras, E | 1 |
| Besses, C | 1 |
| Hernando, A | 1 |
| Fontanillas, M | 1 |
| Jhanwar-Uniyal, M | 1 |
| Gulati, SC | 1 |
| Celik, I | 1 |
| Güler, N | 1 |
| Ozyilkan, O | 1 |
| Hayran, M | 1 |
| Firat, D | 1 |
| Yule, SM | 1 |
| Price, L | 1 |
| Pearson, AD | 1 |
| Boddy, AV | 1 |
| Mayer, J | 1 |
| Korístek, Z | 1 |
| Vásová, I | 1 |
| Müllerová, I | 1 |
| Král, Z | 1 |
| Navrátil, M | 1 |
| Klabusay, M | 1 |
| Vorlícek, J | 1 |
| Vodvárka, P | 1 |
| Hejlová, N | 1 |
| Penka, M | 1 |
| Krahulcová, E | 1 |
| Tomíska, M | 1 |
| Adam, Z | 1 |
| Hájek, R | 1 |
| Straub, G | 1 |
| Borchmann, P | 1 |
| Ubelacker, R | 1 |
| Münch, R | 1 |
| Itoh, K | 1 |
| Igarashi, T | 1 |
| Ohtsu, T | 1 |
| Wakita, H | 1 |
| Watanabe, Y | 1 |
| Fujii, H | 1 |
| Minami, H | 1 |
| Sasaki, Y | 1 |
| Drumea, K | 1 |
| Plantier-Colcher, I | 1 |
| Dupriez, B | 2 |
| Simon, M | 1 |
| Detourmignies, L | 1 |
| Jouet, JP | 1 |
| Fenaux, P | 1 |
| Bauters, F | 1 |
| Morel, P | 1 |
| Bachier, C | 1 |
| Preti, H | 1 |
| Sarris, AH | 2 |
| Weber, D | 1 |
| Younes, A | 5 |
| Kung, FH | 1 |
| Harris, MB | 1 |
| Krischer, JP | 1 |
| Rodriguez, J | 2 |
| Fayad, L | 1 |
| Santiago, M | 1 |
| Hess, M | 1 |
| Romaguera, J | 1 |
| Glassman, JR | 2 |
| Elkin, N | 1 |
| Reinhardt, W | 1 |
| Sauter, V | 1 |
| Jockenhövel, F | 1 |
| Kummer, G | 1 |
| Uppenkamp, M | 1 |
| Witzke, O | 1 |
| Philipp, T | 1 |
| Reinwein, D | 1 |
| Mann, K | 1 |
| McQuaker, I | 1 |
| Haynes, A | 1 |
| Stainer, C | 1 |
| Byrne, J | 1 |
| Yakisan, E | 1 |
| Zimmermann, M | 1 |
| Mann, G | 1 |
| Ebell, W | 1 |
| Klingebiel, T | 1 |
| Graf, N | 1 |
| Kremens, B | 1 |
| Plüss, HJ | 1 |
| Zintl, F | 1 |
| Hedrick, EE | 2 |
| Hunte, S | 2 |
| Coady-Lyons, N | 1 |
| Agus, DB | 1 |
| Goy, A | 1 |
| Jurcic, J | 1 |
| Noy, A | 1 |
| O'Brien, J | 1 |
| Straus, DS | 1 |
| Childs, B | 1 |
| Frank, R | 1 |
| Filippa, D | 1 |
| Louie, D | 1 |
| Preti, A | 1 |
| Inoue, R | 1 |
| Natazuka, T | 1 |
| Shimoyama, M | 1 |
| Tamekane, A | 1 |
| Kajimoto, Y | 1 |
| Iwata, N | 1 |
| Matsuoka, H | 1 |
| Chihara, K | 1 |
| King, K | 1 |
| Champlin, RE | 1 |
| Van Besien, KW | 1 |
| Gajewski, JG | 1 |
| Lauppe, J | 1 |
| Durett, A | 1 |
| Andersson, B | 2 |
| Hagemeister, F | 1 |
| Sarris, A | 2 |
| Ippoliti, C | 1 |
| Blamble, DA | 1 |
| Hester, J | 1 |
| Gee, A | 1 |
| McBride, NC | 1 |
| Ward, MC | 1 |
| Mills, MJ | 1 |
| Eden, AG | 1 |
| Hughes, A | 1 |
| Cavenagh, JD | 1 |
| Lamont, A | 1 |
| Newland, AC | 1 |
| Kelsey, SM | 1 |
| Vela-Ojeda, J | 1 |
| Tripp-Villanueva, F | 1 |
| Montiel-Cervantes, L | 1 |
| Sánchez-Cortés, E | 1 |
| Ayala-Sánchez, M | 1 |
| Guevara-Moreno, ME | 1 |
| García-León, LD | 1 |
| Rosas-Cabral, A | 1 |
| Esparza, MA | 1 |
| González-Llaven, J | 1 |
| Hołowiecki, J | 1 |
| Wojciechowska, M | 1 |
| Krawczyk-Kuliś, M | 1 |
| Wojnar, J | 1 |
| Kachel, L | 1 |
| Kata, D | 1 |
| Markiewicz, M | 1 |
| Donnelly, GB | 1 |
| Priovolos, AC | 1 |
| Qin, J | 1 |
| Lyons, NC | 1 |
| Skovlund, E | 1 |
| Fenstad, GU | 1 |
| Rodriguez, A | 1 |
| Tomany, S | 1 |
| Donato, M | 1 |
| Fiedler, R | 1 |
| Baumann, F | 1 |
| Deschler, B | 1 |
| Osten, B | 1 |
| Wilder, RB | 1 |
| Tucker, SL | 1 |
| Ha, CS | 1 |
| Hess, MA | 1 |
| Cabanillas, FF | 1 |
| Cox, JD | 1 |
| Coleman, M | 1 |
| Leonard, J | 1 |
| Shuster, MW | 1 |
| Kaufman, TP | 1 |
| Vellenga, E | 1 |
| van Agthoven, M | 1 |
| Croockewit, AJ | 1 |
| Verdonck, LF | 1 |
| Wijermans, PJ | 1 |
| van Oers, MH | 1 |
| Volkers, CP | 1 |
| van Imhoff, GW | 1 |
| Kingma, T | 1 |
| Uyl-de Groot, CA | 1 |
| Fibbe, WE | 1 |
| Lee, EJ | 1 |
| Petroni, GR | 1 |
| Schiffer, CA | 1 |
| Freter, CE | 1 |
| Johnson, JL | 1 |
| Barcos, M | 1 |
| Frizzera, G | 1 |
| Bloomfield, CD | 1 |
| Peterson, BA | 1 |
| Jain, S | 1 |
| Moger, V | 1 |
| Kumari, S | 1 |
| Varma, S | 1 |
| Bosly, A | 1 |
| Lepage, E | 1 |
| Fillet, G | 1 |
| Herbrecht, R | 3 |
| Divine, M | 1 |
| Nouvel, C | 1 |
| Deconninck, E | 1 |
| Bordessoule, D | 1 |
| Gaulard, P | 1 |
| Primavera, A | 1 |
| Audenino, D | 1 |
| Cocito, L | 1 |
| Moskowitz, C | 1 |
| Shimizu, K | 1 |
| Shinkai, K | 1 |
| Steinke, B | 3 |
| Bross, K | 2 |
| Reinold, HM | 2 |
| Heim, ME | 3 |
| Schalk, KP | 1 |
| Heidemann, E | 2 |
| Josten, K | 2 |
| Arnold, H | 2 |
| Manegold, C | 1 |
| Hoffman, I | 1 |
| Damonte, JC | 1 |
| Dufour, P | 2 |
| Maloisel, F | 1 |
| Liu, KL | 1 |
| Ortiz, S | 1 |
| Bergerat, JP | 2 |
| Oberling, F | 2 |
| Goss, PE | 2 |
| Miller, LJ | 1 |
| Eaton, VE | 1 |
| Case, DC | 2 |
| Santarelli, MT | 1 |
| Carey, RW | 1 |
| Anderson, J | 2 |
| Gottlieb, A | 2 |
| Rosenblatt, E | 1 |
| Wollner, M | 1 |
| Robinson, E | 1 |
| Anders, CH | 1 |
| Niederle, N | 1 |
| Nagel-Hiemke, M | 1 |
| Schmidt, CG | 2 |
| Meusers, P | 3 |
| Brack, N | 1 |
| Dornoff, W | 1 |
| Enne, W | 2 |
| Gassmann, W | 1 |
| Gerhartz, H | 2 |
| Hallek, M | 1 |
| Heise, J | 1 |
| Gutiérrez, J | 1 |
| Osorio, G | 1 |
| García, H | 1 |
| Vacarezza, R | 1 |
| Cao, C | 1 |
| Paradiso, A | 1 |
| Guida, M | 1 |
| Berardi, F | 1 |
| Mirza, MR | 1 |
| Brincker, H | 1 |
| Shepherd, FA | 1 |
| Warner, E | 1 |
| Baker, MA | 1 |
| Farquharson, HA | 1 |
| Buick, S | 1 |
| Iwasaku-Fujimoto, M | 1 |
| Fujiwara, F | 1 |
| Todo, S | 1 |
| Morioka, Y | 1 |
| Imashuku, S | 1 |
| Bruntsch, U | 1 |
| Steinhauer, EU | 1 |
| Lötzke, E | 1 |
| Lindemalm, C | 1 |
| Tada, A | 1 |
| Ohnoshi, T | 1 |
| Hayashi, K | 1 |
| Ueoka, H | 1 |
| Ueno, K | 1 |
| Murashima, M | 1 |
| Mizuta, J | 1 |
| Yoshida, M | 1 |
| Kimura, I | 1 |
| Thiel, E | 3 |
| Dörken, B | 1 |
| Engert, W | 1 |
| Fuchs, R | 1 |
| Hagen-Aukamp, CH | 1 |
| Neubauer, A | 1 |
| Stacher, A | 2 |
| Krüger, HU | 1 |
| Kraft, H | 1 |
| Günther, E | 1 |
| Busch, FW | 1 |
| von Kalle, AK | 1 |
| Schaadt, M | 1 |
| Kraft, A | 1 |
| Löffler, B | 1 |
| Richter, C | 1 |
| Hofmann, I | 1 |
| Garcia, JJ | 1 |
| Duclos, B | 1 |
| Meier, CR | 1 |
| Schoetensack, B | 1 |
| Anders, C | 1 |
| Höffken, K | 1 |
| Osieka, R | 1 |
| Sampi, K | 1 |
| Masaoka, T | 1 |
| Takagi, T | 1 |
| Sakamoto, S | 1 |
| Mikuni, C | 1 |
| Kano, Y | 1 |
| Gad-el-Mawla, N | 1 |
| Hussein, MH | 1 |
| Abdel-Hadi, S | 1 |
| el-Taneer, O | 1 |
| Sangster, G | 1 |
| Patton, WN | 1 |
| Harris, RI | 1 |
| Grieve, RJ | 1 |
| Leyland, MJ | 1 |
| Ervin, TJ | 1 |
| Li, GC | 1 |
| Brock, N | 1 |
| Li, JQ | 1 |
| Guan, ZZ | 1 |
| He, YJ | 1 |
| Norberg, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841] | Phase 3 | 250 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| Phase 3 Study of Dose-Dense Therapy Versus CHOP in Aggressive Non-Hodgkin's Lymphoma[NCT00517894] | 0 participants | Expanded Access | No longer available | ||||
| Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas[NCT00554164] | Phase 3 | 1,073 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Clinical Efficacy and Safety of IBER Salvage Treatment Followed by Ibrutinib Maintenance for Transplant-ineligible Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL): a Multicenter, Single-arm, Prospective Phase II Study[NCT04066920] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-10-01 | Not yet recruiting | ||
| Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results[NCT00324467] | Phase 2 | 150 participants (Actual) | Interventional | 2006-08-31 | Active, not recruiting | ||
| A Single Center, Prospective Study to Compare the Quality and Quantity of the Cellular Content of M-PRP Harvested After Peripheral Mobilization of Progenitor Cells Using Filgrastim Versus Pegfilgrastim[NCT05573386] | 10 participants (Anticipated) | Observational | 2021-08-09 | Recruiting | |||
| A Randomised, Multi-Centre, Double-Blind Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim for Autologous Transplantation in Subjects With Non-Hodgkin's Lymphoma[NCT00117455] | Phase 2 | 0 participants | Interventional | Completed | |||
| Burkimab:Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old)[NCT00388193] | Phase 2 | 20 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| Treatment Regimen or Children or Adolescent With Mature B-cell NHL or B-AL in China[NCT02405676] | Phase 2/Phase 3 | 200 participants (Anticipated) | Interventional | 2015-01-31 | Active, not recruiting | ||
| Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.[NCT05049473] | Phase 2 | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| HIGH INTENSITY, BRIEF DURATION CHEMOTHERAPY FOR DIFFUSE SMALL NONCLEAVED CELL LYMPHOMA AND THE L-3 SUBTYPE OF ALL: A PILOT STUDY OF A MULTIDRUG REGIMEN[NCT00002494] | Phase 2 | 134 participants (Actual) | Interventional | 1992-05-31 | Completed | ||
| PILOT MULTINATIONAL PROTOCOLS IN ACUTE LYMPHOBLASTIC LEUKEMIA AND DIFFUSE NON-HODGKIN'S LYMPHOMA[NCT00018954] | Phase 2 | 0 participants | Interventional | 1992-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 reviews available for ifosfamide and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Extra-nodal Cytokeratin-Positive Interstitial Reticulum Cell Sarcoma Presenting as a Colonic Polyp: Report of a Rare Case with Review of Literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colon; Col | 2020 |
Current role and future perspectives for ifosfamide in the treatment of malignant non-Hodgkin's lymphoma--results from an expert meeting.
Topics: Humans; Ifosfamide; Lymphoma, Non-Hodgkin | 2003 |
Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Etoposide; Fo | 2003 |
Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin's lymphoma and Hodgkin's disease: the Italian experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Epirubicin; Etoposide; Hod | 2003 |
Non-hodgkins lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Mo | 2003 |
Ifosfamide in hematological malignancies of adults.
Topics: Adult; Antineoplastic Agents, Alkylating; Burkitt Lymphoma; Hematologic Neoplasms; Hodgkin Disease; | 2003 |
Improving second-line therapy in aggressive non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2004 |
Transverse nail ridgings (Beau's lines) induced by chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Dexame | 1994 |
[Malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; | 1994 |
The use of ifosfamide, carboplatin, and etoposide in children with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Humans; Ifosfamide; L | 1995 |
[Recent progress on therapy of malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Humans; Ifosfa | 1993 |
Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Cyc | 1993 |
Ifosfamide in the treatment of non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Ste | 1996 |
Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 1996 |
Ifosfamide in the treatment of lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 1996 |
Factors that influence prognosis of intermediate-grade lymphomas at relapse.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cisplatin; | 1996 |
Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials a | 2000 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
New perspectives in the treatment of non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Ifosfamide; Lympho | 1992 |
Ifosfamide-induced neurotoxicity: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Humans; Ifos | 1992 |
European experience with ifosfamide in lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Etoposide; Europe; Hodgkin Disease; Human | 1989 |
79 trials available for ifosfamide and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; L | 2023 |
Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; | 2013 |
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neop | 2016 |
Treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free S | 2008 |
[DNCE regimen for treatment of refractory or relapsed aggressive and highly aggressive non-Hodgkin lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2008 |
Dose-dense therapy improves survival in aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2010 |
Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2010 |
Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas--the PETAL trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2009 |
A pilot study on the use of outpatient fractionated ifosfamide, carboplatin and etoposide (ICE) and pegfilgrastim as a salvage and mobilizing regimen for relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide | 2012 |
A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cy | 2002 |
A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cycloph | 2002 |
Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigen | 2002 |
New insights into the clinical pharmacokinetics of trofosfamide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Biological Availability; Cyclophos | 2002 |
A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle Lymphoma Group Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; | 2003 |
Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Etoposide; Hum | 2004 |
Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free | 2005 |
Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; | 2005 |
Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: the experience of a single center in Brazil.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brazil; Cytarabine; Developing Co | 2006 |
Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Hematopo | 2007 |
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Thera | 2007 |
Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dose | 2007 |
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carmusti | 2008 |
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carmusti | 2008 |
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carmusti | 2008 |
A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carboplatin; Carmusti | 2008 |
Peripheral T-cell non-Hodgkin's lymphomas of low malignancy: prospective study of 25 patients with pleomorphic small cell lymphoma, lymphoepitheloid cell (Lennert's) lymphoma and T-zone lymphoma. The Kiel Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1994 |
CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
Topics: Actuarial Analysis; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocol | 1995 |
Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cispl | 1995 |
Peripheral blood stem cell mobilization following salvage chemotherapy (IAPVP-16) plus granulocyte colony-stimulating factor and autografting for non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Gr | 1995 |
[MMIP chemotherapy for the treatment of the relapsed and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifos | 1995 |
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 1995 |
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 1995 |
Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cis | 1994 |
Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1994 |
Pilot study and randomised trial of mitozantrone and ifosfamide for relapsed non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma group (SNLG) Working Party on Therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Lymphoma, N | 1993 |
EPIC: an effective low toxicity regimen for relapsing lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Drug A | 1993 |
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 1996 |
DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Etoposide; Fe | 1995 |
Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclopho | 1996 |
Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Presch | 1996 |
Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Diseas | 1996 |
Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Busulfan; Combined Mod | 1996 |
Chemosensitive epidural spinal cord disease in non-Hodgkins lymphoma.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dox | 1996 |
A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Etoposide; Female; Humans | 1997 |
Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cell Separa | 1997 |
Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy P | 1997 |
Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Idarubicin; | 1997 |
High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tran | 1997 |
Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; | 1998 |
[Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hem
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Data Interpretation, S | 1998 |
Phase II trial of MINE as a front-line therapeutic modality in intermediate- and high-grade non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; | 1998 |
[Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etopos | 1998 |
DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dexamethas | 1998 |
Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Fem | 1998 |
Dexamethasone, cytarabine, ifosfamide, and cisplatin as salvage therapy in non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; F | 1999 |
The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma. A prospective study of 71 consecutive cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytara | 1999 |
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabin | 1998 |
Ifosfamide/carboplatin/etoposide (ICE), an effective salvaging therapy for recurrent malignant non-Hodgkin lymphoma of childhood: a Pediatric Oncology Group phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplati | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Burkitt Lymphoma; Chi | 1999 |
Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Movement; | 1999 |
Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Female; Humans; | 1999 |
Feasibility of high-dose chemotherapy without stem cell support as a first-line treatment for non-Hodgkin's aggressive lymphoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Cyclophosphami | 2000 |
Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; | 1999 |
Epic as an effective, low toxicity salvage therapy for patients with poor risk lymphoma prior to beam high dose chemotherapy and peripheral blood progenitor cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; | 1999 |
Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryopreservation; Cyc | 2000 |
Ifosfamide, etoposide, epirubicine, and G-CSF: an effective mobilization regimen for PBSCT in heavily pretreated patients.
Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Etoposide; Female; Granulocyte Colon | 2000 |
Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Follow-Up S | 2001 |
Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 2001 |
DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Drug Re | 2001 |
Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chi- | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2001 |
Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug | 2001 |
Cyclic alternating chemotherapy of high-grade malignant non-Hodgkin lymphomas with VIM-Bleo and CHOP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1992 |
Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: cancer and leukemia group B study 8753.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration | 1992 |
Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1991 |
MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Hodgkin Disease; Humans; Ifo | 1991 |
Sequential versus alternating chemotherapy for high-grade non-Hodgkin's lymphomas: preliminary results of a phase III multicentre trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dose-Re | 1990 |
German-Austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modali | 1988 |
[Multicenter prospective risk-adapted study on the therapy of non-Hodgkin's lymphomas of high malignancy. Use of COP-BLAM/IMVP-16 and randomized adjuvant radiotherapy--study concept and preliminary results].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modali | 1988 |
[Sequential alternating chemotherapy of highly malignant non-Hodgkin's lymphomas with VIM-Bleo and CHOP. Initial results].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Cy | 1989 |
[Risk-adapted therapy of highly malignant non-Hodgkin's lymphomas with COP-BLAM/IMVP-16: a prospective multicenter study].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials | 1989 |
[Aclarubicin-combined combination chemotherapy in patients with refractory or relapsed non-Hodgkin's lymphoma].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Drug Resi | 1989 |
94 other studies available for ifosfamide and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 2022 |
Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Etoposid | 2022 |
PD-1 blockade combined with ICE regimen in relapsed/refractory diffuse large B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Lymphoma | 2023 |
Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin | 2020 |
Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deo | 2020 |
Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 2015 |
Finding the Optimal Conditioning Regimen for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation: A Retrospective Comparison of BEAM and High-Dose ICE.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Do | 2016 |
Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2015 |
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Burkitt Lymphoma; Central Ner | 2016 |
Evaluation of a method for calculating carboplatin dosage in DeVIC ± R therapy (combination therapy of dexamethasone, etoposide, ifosfamide and carboplatin with or without rituximab) as a salvage therapy in patients with relapsed or refractory non-Hodgkin
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dexamethasone; | 2016 |
Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.
Topics: Antigens, CD34; Antineoplastic Agents; Epirubicin; Etoposide; Hematopoietic Stem Cell Mobilization; | 2016 |
Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Tra | 2016 |
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cy | 2009 |
Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Biomarkers; Child; Cyclophosphamide; Dose-Resp | 2009 |
Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Etoposide; Fe | 2009 |
A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Central Nervous System Neoplasms; Cy | 2009 |
Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexameth | 2009 |
Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; D | 2011 |
Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Dexamethasone; Etoposide; Hodgkin Disease; Hu | 2011 |
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine | 2011 |
Rituximab significantly improves complete response rate in patients with primary CNS lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Central Nervous System N | 2012 |
Favorable course of pericardial angiosarcoma under paclitaxel followed by pazopanib treatment documented by cardiovascular magnetic resonance imaging.
Topics: Adrenal Cortex Hormones; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Early relapses in patients with primary CNS lymphoma treated with methotrexate-based chemotherapy without consolidating whole brain irradiation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nerv | 2013 |
Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Comb | 2002 |
High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C | 2002 |
Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Ifosfami | 2002 |
High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Child, Presch | 2003 |
Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2003 |
Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide | 2003 |
Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Ambulatory Care; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antine | 2003 |
Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Epirubicin; Etop | 2004 |
Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic A | 2005 |
[Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Dexametha | 2005 |
IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; F | 2005 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carm | 2005 |
[Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Daca | 2006 |
[IEMAD (modified MIME) therapy for refractory or relapsed non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; | 2006 |
False-positive restaging PET scans involving the spleen in two patients with aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigen | 2006 |
[Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2006 |
[Concurrent chemo-radiotherapy for localized refractory non-Hodgkin's lymphoma--report of two cases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; D | 2007 |
The effect of short-term intensive chemotherapy on reactivation of tuberculosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxo | 2007 |
Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytar | 1995 |
[Increased blood cell destruction during vigorous regeneration of bone marrow after CAMBO-VIP chemotherapy for non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cell Count | 1994 |
Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marr | 1995 |
Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Mar | 1995 |
Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine | 1995 |
Results of treatment of small non-cleaved cell lymphoma in patients without positive HIV serology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Cyclophospha | 1993 |
[Combination of etoposide, cisplatin and ifosfamide (VPH) in the salvage chemotherapy of relapsing or refractory aggressive malignant lymphoma. Study of 51 patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Femal | 1994 |
Ifosfamide extravasation.
Topics: Chondroitinsulfatases; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Ifosfa | 1994 |
Three-year results of MIM salvage treatment for refractory/relapsed intermediate grade NHL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrex | 1995 |
[Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dexamethasone; | 1994 |
High-dose carboplatin, etoposide and ifosfamide and autologous stem cell rescue in the treatment of non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Combined M | 1993 |
IEVM chemotherapy with rhGM-CSF support for aggressive non-Hodgkin's lymphomas: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Granulocyte-Macr | 1993 |
Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cyclophosphamide; Cyta | 1996 |
Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin's lymphomas: a Swedish national prospective study. Swedish Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined M | 1996 |
Ifosfamide in the treatment of pediatric malignancies.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 1996 |
High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma: pattern of failure and implications for involved-field radiotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Etoposi | 1997 |
Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Disease-Free S | 1997 |
Administration of MINE protocol in untreated patients with intermediate and high grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; | 1997 |
Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The | 1998 |
p53 gene mutation in the bone-marrow of a patient with diffuse mixed cell type lymphoma at diagnosis predicting eventual progression to large cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Dexamethasone; Disease Progr | 1998 |
Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.
Topics: Adolescent; Antineoplastic Agents; Biotransformation; Brain Neoplasms; Child; Child, Preschool; Cycl | 1997 |
Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 1999 |
The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposi | 1999 |
Unique alterations of thyroid function parameters after i.v. administration of alkylating drugs (cyclophosphamide and ifosfamide).
Topics: Adult; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexameth | 1999 |
Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease.
Topics: Adult; Antigens, CD34; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematop | 1999 |
High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Eto | 2000 |
Should we always choose a nonparametric test when comparing two apparently nonnormal distributions?
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dat | 2001 |
Haemoperfusion combined with haemodialysis in ifosfamide intoxication.
Topics: Adult; Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Hemoperfusion; Humans; Ifosfami | 2001 |
Ifosfamide induced encephalopathy following chemotherapy of Non-Hodgkin's Lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Female; Humans; Ifosfamide; Lymphoma, Non-H | 2001 |
Ifosfamide encephalopathy and nonconvulsive status epilepticus.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Diazepam; Electroencephalography; Epileps | 2002 |
Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administrat | 2002 |
Alternating non-cross-resistant chemotherapy for non-Hodgkin's lymphoma of intermediate-grade and high-grade malignancy. A pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclo | 1992 |
Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin | 1992 |
Etoposide, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cyclophosphamid | 1992 |
Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexametha | 1992 |
Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation; | 1991 |
[Malignant lymphomas. Preliminary report of the National Protocol of Antineoplastic Drugs].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1991 |
Experience with salvage regimens at M.D. Anderson Hospital.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Evaluation; Etoposide; F | 1991 |
Ifosfamide plus mitoxantrone as salvage treatment in non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; | 1991 |
Dexamethasone/ifosfamide/cisplatin/etoposide (DICE) as therapy for patients with advanced refractory non-Hodgkin's lymphoma: preliminary report of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Dexamethasone; | 1991 |
[Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
Topics: Bone Neoplasms; Child; Cyclophosphamide; Cystitis; Female; Hematuria; Humans; Ifosfamide; Leukemia; | 1990 |
Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Follow-Up Studies; H | 1990 |
[Combination chemotherapy of diffuse large-cell non-Hodgkin's lymphoma--superiority of the adriamycin combination].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1987 |
Response-oriented therapy with CHOP and VIM-Bleo in high-grade malignant non-Hodgkin's lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Evalu | 1988 |
VP-16, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; | 1989 |
Sequential combination chemotherapy (CABOPP/VIM) for the treatment of high-grade malignant non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide | 1989 |
Childhood non-Hodgkin's lymphoma in Egypt: preliminary results of treatment with a new ifosfamide-containing regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 1989 |
Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfamide, methotrexate and etoposide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Evaluation; Etoposide | 1989 |
Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Evaluation; Hematologic Diseases; Hematuria; Humans | 1988 |
Ifosfamide and Mesna in advanced malignancies.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Lymphom | 1988 |
Ifosfamide combinations in salvage treatment of non-Hodgkin lymphoma.
Topics: Cytarabine; Doxorubicin; Drug Evaluation; Humans; Ifosfamide; Lymphoma, Non-Hodgkin | 1986 |